Table 3.

Recognized gene defects, gene polymorphisms, and karyotype abnormalities in patients with (systemic) mastocytosis.

FindingReported inPatients with:EstimatedFrequency inPatients with SM
Abbreviations: CM, cutaneous mastocytosis; SM, systemic mastocytosis; SM-AHNMD, SM with an associated hematologic clonal non-mast cell lineage disease; HES, hypereosinophilic syndrome; n.k., not known 
Gene defects 
    c-kit D816V all variants of SM (rarely in CM) > 80% 
    c-kit D816Y CM, SM, SM-AHNMD < 5% 
    c-kit D816F CM, SM < 5% 
    c-kit D816H SM-AHNMD < 5% 
    c-kit D820G ASM < 5% 
    c-kit V560G SM < 5% 
    c-kit F522C SM < 5% 
    c-kit E839K CM < 5% 
    c-kit V530I SM-AML < 5% 
    c-kit K509I SM (familial type) < 5% 
    FIP1L1/PDGFRA SM-HES, SM with eosinophilia < 5% 
Gene polymorphisms 
    IL-4Rα Q576R CM, indolent SM (ISM) n.k. 
Karyotype abnormalities 
    del 20(q12) SM, SM-AHNMD < 5% 
    +9 SM, SM-AHNMD < 5% 
    t(8;21) SM-AML M2 < 5% 
FindingReported inPatients with:EstimatedFrequency inPatients with SM
Abbreviations: CM, cutaneous mastocytosis; SM, systemic mastocytosis; SM-AHNMD, SM with an associated hematologic clonal non-mast cell lineage disease; HES, hypereosinophilic syndrome; n.k., not known 
Gene defects 
    c-kit D816V all variants of SM (rarely in CM) > 80% 
    c-kit D816Y CM, SM, SM-AHNMD < 5% 
    c-kit D816F CM, SM < 5% 
    c-kit D816H SM-AHNMD < 5% 
    c-kit D820G ASM < 5% 
    c-kit V560G SM < 5% 
    c-kit F522C SM < 5% 
    c-kit E839K CM < 5% 
    c-kit V530I SM-AML < 5% 
    c-kit K509I SM (familial type) < 5% 
    FIP1L1/PDGFRA SM-HES, SM with eosinophilia < 5% 
Gene polymorphisms 
    IL-4Rα Q576R CM, indolent SM (ISM) n.k. 
Karyotype abnormalities 
    del 20(q12) SM, SM-AHNMD < 5% 
    +9 SM, SM-AHNMD < 5% 
    t(8;21) SM-AML M2 < 5% 

or Create an Account

Close Modal
Close Modal